The clinical-stage biotechnology company revealed that its once-daily 50mg dose of obefazimod achieved clinically meaningful improvements across all endpoints in patients with moderate-to-severe ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback